y critical given the progressive and often silent nature of the disease, with many patients already experiencing some degree of kidney damage by the time they’re diagnosed. Without effective intervention, the risk of renal failure – and the need for dialysis or transplant – remains alarmingly high.”

In the study, 17 patients with IgA nephropathy were treated with mezagitamab as an add-on to stable background therapy, and 13 patients continued into the long-term follow-up period. At Week 96 – 18 months after the last dose – kidney function remained stable (mean change in eGFR from baseline +2.5; 95% CI: −1.8, +7.6; n=12) and patients sustained a 55.2% (95% CI: 30.2, 72.6; n=13) mean reduction in proteinuria (protein in the urine) measured using a urine protein-creatinine ratio (UPCR).1Sustained reductions of 50.1% in Gd-IgA1 and complete recovery toward baseline in IgG were observed by Week 96.1Hematuria (blood in the urine) was resolv
=*=*=*=*=*=
当前为第3/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页